Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis

Turkish Journal of Gastroenterology

Volumn 23, Issue 5, 2012, Pages 560-568

  Kabaçam, Gökhan ^a   Dalekos, George N ^b   Ca̧kaloǧlu, Yilmaz ^c   Zachou, Kalliopi ^b   Bock, Thomas ^d   Erhardt, Andreas ^e   Zeuzem, Stefan ^e   Tabak, Fehmi ^f   Yalçin, Kendal ^g   Bozdayi, A Mithat ^a   Dienes, Hans P ^h   Bozkaya, Hakan ^a   Manns, Michael ⁱ   Wedemeyer, Heiner ⁱ   Yurdaydin, Cihan ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b UNIVERSITY OF THESSALY   (Greece)

^c ISTANBUL UNIVERSITY   (Turkey)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f ISTANBUL UNIVERSITY   (Turkey)

^g DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^h UNIVERSITY OF COLOGNE   (Germany)

ⁱ HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cirrhosis; Hepatitis delta; Pegylated interferon; Therapy

Indexed keywords

ADEFOVIR DIPIVOXIL; PEGINTERFERON ALPHA2A; PLACEBO; VIRUS RNA;

ABDOMINAL PAIN; ADULT; ADVANCED LIVER DISEASE; ARTHRALGIA; ARTICLE; AUTOIMMUNE HEPATITIS; BLEEDING; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DELTA AGENT HEPATITIS; DEPRESSION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FOLLOW UP; GINGIVA BLEEDING; HAIR LOSS; HEADACHE; HEPATITIS DELTA VIRUS; HUMAN; HUMAN TISSUE; LEUKOPENIA; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; NEUTROPENIA; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; SIDE EFFECT; SLEEP DISORDER; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUBERCULOSIS; VIRUS REACTIVATION;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; BIOPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPATITIS D, CHRONIC; HEPATITIS DELTA VIRUS; HUMANS; INTERFERON-ALPHA; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RNA, VIRAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865775958     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: 10.4318/tjg.2012.0538     Document Type: Article

References (36)

1. Romeo R, Del Ninno E, Rumi M, et al. A 28-year study of the course of hepatitis δ infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology 2009; 136: 1629-38.
2. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 2010; 7: 31-40.
3. Yurdaydin C, Idilman R, Bozkaya H, Bozdayi AM. Natural history and treatment of chronic delta hepatitis. J Viral Hepat 2010; 17: 749-56.
4. Erhardt A, Gerlich W, Starke C, et al. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int 2006; 26: 805-10. (Pubitemid 44172032)
5. Castelnau C, Le Gal F, Ripault MP, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 2006; 44: 728-35. (Pubitemid 44433730)
6. Niro GA, Ciancio A, Gaeta GB, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology 2006; 44: 713-20. (Pubitemid 44433728)
7. Garripoli A, Di Marco V, Cozzolongo R, et al. Ribavirin treatment for chronic hepatitis D: a pilot study. Liver 1994; 14: 154-7. (Pubitemid 24221772)
8. Yurdaydin C, Bozkaya H, Gürel S, et al. Famciclovir treatment of chronic delta hepatitis. J Hepatol 2002; 37: 266-71.
9. Niro GA, Ciancio A, Tillman HL, et al. Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. Aliment Pharmacol Ther 2005; 22: 227-32. (Pubitemid 41153065)
10. Yurdaydin C, Bozkaya H, Onder FO, et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat 2008; 15: 314-21. (Pubitemid 351326903)
11. Wedemeyer H, Yurdaydin C, Dalekos G, et al. Peg-interferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011; 364: 322-31.
12. Kabaçam G, Önder FO, Yakut M, et al. Entecavir treatment of chronic hepatitis D. Clin Infect Dis 2012; 55: 645-50.
13. Günşar F, Akarca US, Ersöz G, et al. Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther 2005; 10: 721-6. (Pubitemid 41376851)
14. Kaymakoǧlu S, Karaca C, Demir K, et al. Alpha interferon and ribavirin combination therapy of chronic hepatitis D. Antimicrob Agents Chemother 2005; 49: 1135-8. (Pubitemid 40327735)
15. Janssen HLA, Brouwer JT, Nevens F, et al. Fatal hepatic decompensation associated with interferon alfa. BMJ 1993; 306: 107-8. (Pubitemid 23010440)
16. Buster EHC, Hansen BE, Buti M, et al. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology 2007; 46: 388-94. (Pubitemid 47344773)
17. Heathcote EJ, Shiffman ML, Cooksley GE, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673-80.
18. Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis. Natural history and treatment. Sem Liver Dis 2006; 26: 142-52.
19. Farci P, Mandas A, Coiana A, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med 1994; 330: 88-94.
20. Saracco G, Rosina F, Brunetto MR, et al. Rapidly progressive HBsAg-positive hepatitis in Italy. The role of hepatitis delta infection. J Hepatol 1987; 5: 284-81.
21. Su CW, Huang YH, Huo TI, et al. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology 2006; 130: 1625-35.
22. Kiesslich D, Crispin MA, Santos C, et al. Influence of hepatitis B virus (HBV) genotype on the clinical course of disease in patients coinfected with HBV and hepatitis delta virus. J Infect Dis 2009; 199: 1608-11.
23. Ishak K, Baptista A, Bianchi I, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
24. Flink HJ, Sprengers D, Hansen BE, et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon (alpha)-2b therapy. Gut 2005; 54: 1604-9. (Pubitemid 41531780)
25. Zachou K, Yurdaydin C, Drebber U, et al. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int 2010; 30: 430-7.
26. Mederacke I, Bremer B, Heidrich B, et al. Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics. J Clin Microbiol 2010; 48: 2022-9.
27. Everson GT, Hoefs JC, Seef LB, et al. Impact of severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial. Hepatology 2006; 44: 1675-84. (Pubitemid 44953672)
28. Hadziyannis SJ, Sette Jr H, Morgan TR, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
29. Bruno S, Shiffman ML, Roberts SK, et al. Efficacy and safety of peginterferon alfa 2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 2010; 51: 388-97.
30. Shindo M, Hamada K, Nishioji K, et al. The predictive value of liver fibrosis in determining the effectiveness of interferons and lamivudine therapies for chronic hepatitis B. J Gastroenterol 2004; 39: 260-7. (Pubitemid 38519432)
31. Telesca C, Angelico M, Piccolo P, et al. Interferon-alpha treatment of hepatitis D induces tuberculosis exacerbation in an immigrant. J Infect 2007; 54: 223-6.
32. Perillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120: 1009-22.
33. Piratvisuth T, Marcellin P, Lau G, et al. ALT flares and sustained ALT response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a, p peginterferon alfa-2a plus lamivudine or lamivudine alone (Abstract). Hepatology 2004; 40: 656A.
34. Tassopoulos NC, Vafiadis I, Tsantoulas D, et al. Interferon-α2b monotherapy in patients with chronic hepatitis C and persistently normal or near normal aminotransferase activity: a randomized, controlled study. J Interferon Cytokine Res 2002; 22: 365-9. (Pubitemid 34499718)
35. Heidrich B, Wedemeyer H, Bektafl M, et al. HBeAg-positive delta hepatitis: virological, biochemical and clinical features in a large European multicenter database (Abstract). Hepatology 2008; 48: 1184A.
36. Wu JC, Chen TZ, Huang YS, et al. Natural history of hepatitis D viral superinfection: significance of viremia detected by polymerase chain reaction. Gastroenterology 1995;108:796-802.